Both in Pharmaceuticals
AnaptysBio vs Ultragenyx Pharmaceutical
Over the past year ANAB returned +116.5% and RARE returned −49.5%; their daily moves had a correlation of 0.08.
ANAB +116.5% RARE −49.5%Growth of $1, one year, split-adjusted
| Metric | ANAB | RARE |
|---|---|---|
| Price | $50.37 | $15.32 |
| Market cap | $1.51B | $1.51B |
| Today | −0.85% | +6.32% |
| 1 month | −10.5% | −40.2% |
| 6 months | −9.1% | −20.6% |
| Year to date | +3.9% | −33.4% |
| 1 year | +113.6% | −47.3% |
| Revenue growth (YoY) | −8.0% | +28.1% |
| Gross margin | 100.0% | 84.1% |
| Net margin | −206.9% | −43.0% |
| P/E (TTM) | — | — |
| Price / sales | 6.5× | 2.1× |
| Net cash | $286.5M | $292.0M |
| Dividend yield | — | — |
| Volatility (60d) | 61.4% | 127.9% |
| Short % of float | 31.1% | 17.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).